TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer

Bibliographic Details
Title: TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer
Authors: Ikumi Kuno, Daisuke Takayanagi, Yuka Asami, Naoya Murakami, Maiko Matsuda, Yoko Shimada, Sou Hirose, Mayumi Kobayashi Kato, Masaaki Komatsu, Ryuji Hamamoto, Kae Okuma, Takashi Kohno, Jun Itami, Hiroshi Yoshida, Kouya Shiraishi, Tomoyasu Kato
Source: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Publisher Information: Nature Portfolio, 2021.
Publication Year: 2021
Collection: LCC:Medicine
LCC:Science
Subject Terms: Medicine, Science
More Details: Abstract Targeted sequencing for somatic mutations across the hotspots of 50 cancer-related genes was performed using biopsy specimens to investigate whether clinicopathological factors and genomic alterations correlated with prognosis in locally advanced cervical cancer. Seventy patients diagnosed with International Federation of Obstetrics and Gynecology (FIGO) stage III to IVA cervical cancer underwent radiotherapy or concurrent chemoradiotherapy at the National Cancer Center Hospital between January 2008 and December 2017. Mutations were detected in 47 of 70 [67% of cases; frequency of genetic alterations was as follows: PIK3CA (51%), FBXW7 (10%), PTEN (7.1%), and TP53 (5.7%)]. The Cancer Genome Atlas (TCGA) datasets showed a similar distribution of somatic mutations, but PIK3CA mutation frequency was significantly higher in our cohort than in TCGA datasets (P = 0.028). Patients with TP53 mutation were significantly related to poor progression-free survival (PFS) (hazard ratio [HR] = 3.53, P = 0.042). Patients with tumor diameters > 70 mm were associated with poor prognosis (HR = 2.96, P = 0.0048). Patients with non-HPV16/18 genotypes had worse prognosis than those with HPV16/18 genotypes (HR = 2.15, P = 0.030). Hence, patients with locally advanced cervical cancer, TP53 mutation, large tumor diameter, and non-HPV16/18 genotype were independently correlated with poor PFS, despite concurrent chemoradiotherapy.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2045-2322
Relation: https://doaj.org/toc/2045-2322
DOI: 10.1038/s41598-021-98527-2
Access URL: https://doaj.org/article/01be47dd8ca541d2a942cb3061a4dbb3
Accession Number: edsdoj.01be47dd8ca541d2a942cb3061a4dbb3
Database: Directory of Open Access Journals
More Details
ISSN:20452322
DOI:10.1038/s41598-021-98527-2
Published in:Scientific Reports
Language:English